JPMorgan Resumes Nektar Therapeutics (NKTR) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $38.48 --0%
Rating Summary:
21 Buy, 9 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 2
Rating Summary:
21 Buy, 9 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 2
Join SI Premium – FREE
JPMorgan analyst Jessica Fye resumes coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Neutral rating and a price target of $26.00.
For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.
Shares of Nektar Therapeutics closed at $18.82 yesterday.
You May Also Be Interested In
- Citi initiates ATI Inc. coverage with Buy rating, $229 target
- Bernstein SocGen Group Starts Abbott India Ltd (BOOT:IN) at Market Perform
- UBS Starts SenseTime Group Inc (20:HK) at Neutral
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
